NasdaqCM - Nasdaq Real Time Price • USD
Evaxion Biotech A/S (EVAX)
As of 11:40 AM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | -0.55 | -0.5 | -2.08 | 0.01 |
| Low Estimate | -0.99 | -0.91 | -3.8 | -4.07 |
| High Estimate | -0.12 | -0.09 | -0.36 | 4.1 |
| Year Ago EPS | -2.4 | -2.1 | -8.1 | -2.08 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 4 | 3 |
| Avg. Estimate | 40k | 40k | 4.83M | 18.39M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | 70k | 80k | 14M | 35.17M |
| Year Ago Sales | -- | -- | -- | 4.83M |
| Sales Growth (year/est) | -- | -- | -- | 280.70% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -2.4 | -2.15 | -1.95 | -1.6 |
| EPS Actual | -2.4 | -2.1 | -2.1 | -1.6 |
| Difference | 0 | 0.05 | -0.15 | 0 |
| Surprise % | 0.00% | 2.30% | -7.70% | 0.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.55 | -0.5 | -2.08 | 0.01 |
| 7 Days Ago | -0.55 | -0.5 | -2.08 | 0.01 |
| 30 Days Ago | -0.48 | -0.52 | -3.75 | 4.1 |
| 60 Days Ago | -0.48 | -0.52 | -3.75 | 4.1 |
| 90 Days Ago | -0.48 | -0.52 | -3.75 | -2.34 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | 1 | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | EVAX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 77.10% | -- | -- | 0.30% |
| Next Qtr. | 76.20% | -- | -- | 9.80% |
| Current Year | 74.30% | -- | -- | 4.50% |
| Next Year | 100.50% | -- | -- | 13.40% |
| Next 5 Years (per annum) | -- | -- | -- | 11.06% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/3/2024 |
| Upgrade | Ladenburg Thalmann: Neutral to Buy | 4/2/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/20/2024 |
| Initiated | HC Wainwright & Co.: Buy | 2/12/2024 |
Related Tickers
NRBO NeuroBo Pharmaceuticals, Inc.
3.1400
+3.97%
ENSC Ensysce Biosciences, Inc.
0.5451
-3.83%
BAVA.CO Bavarian Nordic A/S
149.50
-1.06%
GNTA Genenta Science S.p.A.
3.3420
-9.05%
GMAB.CO Genmab A/S
1,972.00
-1.79%
ALK-B.CO ALK-Abelló A/S
126.50
-1.71%
EXPRS2.ST ExpreS2ion Biotech Holding AB (publ)
2.8300
-5.51%
ARTL Artelo Biosciences, Inc.
1.3000
-0.76%
CMND Clearmind Medicine Inc.
1.1824
-0.64%
GUBRA.CO Gubra A/S
294.00
+0.34%